紫鑫品牌怎么样 申请店铺

我要投票 紫鑫在人参行业中的票数:305 更新时间:2025-02-23
紫鑫是哪个国家的品牌?「紫鑫」是 吉林紫鑫药业股份有限公司 旗下著名品牌。由创始人郭春林经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力紫鑫品牌出海!通过在本页面挂载紫鑫品牌的产品链接和联系邮箱,可以提高紫鑫产品曝光!跨境电商爆单神器,目前只要100元/年哦~

紫鑫怎么样

吉林紫鑫药业股份有限公司是吉林省制药生产企业中的后起之秀,1998年5月成立,2007年3月在深交所挂牌上市,是一家集中成药的研发、生产、销售、饮片加工、药用动植物种养殖为一体的高科技股份制企业。公司始终坚持以现代中药和中药现代化为目标,将“以品树人、以德酿药”作为行为准则,致力于中华之瑰宝――中药的研发、生产、销售及中药材的种植,严格按照现代企业制度管理,初步形成了具有一定核心竞争力的中药制药价值链。

紫鑫药业公司现有14个职能部门,6个全资子公司和1个控股公司,分别坐落在长白山脉的南、中、东麓。目前,公司职工总数860人,具有高级职称人员21人,中级职称人员42人,执业药师12人,药师12人。截止到2010年末,资产规模为25.7亿元,实现营业6.4亿元,利税总额超过2.3亿余元,并先后获得“吉林省非公有制经济纳税大户”、“小巨人企业”、“非公有制百强企业”、“吉林省百强民营企业”、“东北三省先进民营企业”、“全国中药百强企业”、“国家级高新技术企业”、“国家级青年文明号企业”、“国家级农业产业化重点龙头企业”等荣誉称号。“紫鑫”商标被评为中国驰名商标和吉林省著名商标。公司董事长郭春生先生当选为吉林省人大代表和省软环境治理监察员。
紫鑫药业的主导品种以治疗心脑血管、消化系统疾病和骨伤类为主,主要产品有活血通脉片、麝香接骨胶囊、醒脑再造胶囊、复方益肝灵片、补肾安神口服液、四妙丸等。剂型包括片剂、胶囊剂、颗粒剂、丸剂、口服溶液剂、合剂和锭剂,全部剂型的生产车间均已获得药品GMP认证。同时公司拥有一支高层次的科研队伍从事新产品的开发、药品知识产权保护、老产品深层次研究等工作,为本公司产品推广和销售打下了坚实的基础。在公司产品中,有21种药品被列入OTC品种,甲类品种18种,乙类品种3种,补肾安神口服液为OTC独家品种;有29种药品品种列入《国家基本医疗保险和工伤保险药品目录》,甲类品种8种,乙类品种21种,四妙丸为独家品种;醒脑再造胶囊、活血通脉片、复方益肝灵片、锁阳补肾胶囊、四妙丸是国家二级中药保护品种,活血通脉片和消炎利胆片是国家级优质优价产品;四妙丸、复方益肝灵片、醒脑再造胶囊、补肾安神口服液和护肝宁片连续多年被命名为吉林省名牌产品。
紫鑫药业一直本着“产品质量关系企业生命,药品质量关系患者生命”和“两个生命观”的质量意识进行着生产经营活动。狠抓中药材的种植质量关。在长白山腹地的中药材种植基地面积达7318公顷,种植林下参、淫羊霍、细辛等重要药材原料,从选种、育苗、种植、除草、施肥,到采收加工、贮藏严格按照GAP标准执行。所产药材均无重金属超标、农药残留等现象,确保了在生产源头上原料质量上乘。采用新型药材种植合作方式。采用“农户-政府-公司-研究所”四位一体的方式培育自己的药材基地,这种方式不仅为公司的原料供应和科研开发提供坚实的质量保障,也带动了当地农村产业化发展,为周边地区提供了上千个就业机会。坚持“挚真质纯”的经营理念。从设备的选型、人才的招揽到技术的使用和原材料的购进都做到了最先进、最好、最精。每批次产品从中药材的投料到半成品、成品及留样观察都按高于国家法定标准来监控,不让一粒不合格的产品出厂。应用先进的生产技术和设备。采用高效液相色谱仪、紫外可见分光光度仪、片剂碎度仪、全自动喷码机等先进检验设备进行质量检测,并把超细粉碎酶技术、二氧化碳超临界萃取技术、薄膜包衣技术、大孔树脂及附分离技术等高科技制药工艺应用到生产中,引进国外现代化生产线,将浸膏烘干、制粒、包衣一步完成,提高了产品科技含量。秉承“销售是企业生存的命脉”的销售理念。公司在经营战略上一直把销售摆在重要位置上,明确提出了大力实施品牌战略的销售策略,建设一流的销售队伍,完善一体化的销售体制,实现了产品定位、物流调度、分配考核、价格管理、市场划分等五个统一,优化了资源配置,全面开创销售工作新局面。坚持“以人为本”的原则。公司在研发激励机制、人力资源配备、技术管理方面制定了切实有效的制度和实施程序。每个员工在公司里都有一个自己的成长和表演的舞台,机会面前人人平等,对于优秀人才和对公司有突出贡献的员工给予重用和重奖,充分调动了全体员工的积极性。义不容辞地担负着社会责任。公司自成立之时起本着造福于社会民众为出发点,积极投身捐助、修路等社会公益事业中,创造近千个就业机会。全身心地履行着社会责任。
紫鑫药业经过了13年成长发展,早已将产品的开发和升级换代作为企业长足发展的关键,建立了以生产一代、储备一代、开发一代阶梯式科研体系,将重点放在治疗肠、胃系统,抗老延年等药品上,加快研制生物制剂,继续开发单味药和小组方品种,重点放在国家级二、三类新药,对现有的重点品种进行提升的再次开发。目前公司正投入大量资金开发心血管类、镇静安神类、妇科用药等系列药品,并结合现代疾病谱的变化,开发了治疗心血管类、内分泌紊乱类、肝病类、消化系统疑难病症的有效药物,形成种类齐全、结构合理的产品系列。
特别是近两年来,紫鑫药业更是响应吉林省政府发展人参产业的号召,大力推动吉林省人参产业的发展。不论是在种植基地上,还是科技产品开发上,都投入了大量的人力、物力、财力。汇同国际领先的研发机构和科学院所,在人参的基因图谱研究、人参酵素解技术的应用、人参酵素产品吃了不上火的人参泡制工艺技术、人参种植重茬技术、以及高残人参的提取物脱残技术领域取得了大成果,并处于世界领先地位。积极引导和规范优质人参的种植和培育市场,努力实现产业的升级和科技成果的有效转化。面对卫生部正式批准吉林省开展人参药食同源试点工作的新形势,紫鑫药业率先将人参引进功能性食品、保健品行业,研发成功100多个品种,其中41个品种已经获准试点生产。紫鑫药业将全力打造紫鑫人参品牌,努力实现吉林省人参产业振兴,重塑中国·吉林人参国际地位。
紫鑫药业将继续秉承“以品树人、以德酿药”的企业宗旨,本着“挚真质纯”的经营理念,坚持“尊重知识、崇尚科学、挖掘传统、开创新知”的经营方针,把世人的健康作为紫鑫的职责。紫鑫药业的未来发展目标也将继承和发扬中医药学特色和优势,努力挖掘中医药学宝库,实现技术创新和产业升级,立足国内市场,开拓国际市场,使公司朝着科技化、专业化、集约化、国际化制药企业集团迈进,为我国中药产业的发展贡献力量。

Jilin Zixin Pharmaceutical Co., Ltd. is a rising star among pharmaceutical production enterprises in Jilin Province. It was founded in May 1998 and listed on Shenzhen Stock Exchange in March 2007. It is a high-tech joint-stock enterprise integrating research and development, production, sales, processing of decoction pieces and cultivation of medicinal animals and plants. The company always adheres to the goal of modernization of modern Chinese medicine and traditional Chinese medicine, takes "cultivating people by products and brewing medicine by virtue" as the code of conduct, devotes itself to the research and development, production, sales and planting of traditional Chinese medicine, the treasure of China, and strictly manages in accordance with modern enterprise system, initially forming a value chain of traditional Chinese medicine with certain core competitiveness. Zixin Pharmaceutical Co., Ltd. has 14 functional departments, 6 wholly-owned subsidiaries and 1 holding company, which are respectively located in the south, middle and east foot of Changbai Mountains. At present, the company has 860 employees, 21 with senior professional titles, 42 with intermediate professional titles, 12 practicing pharmacists and 12 pharmacists. By the end of 2010, the asset scale was 2.57 billion yuan, the business was 640 million yuan, the total profit and tax exceeded 230 million yuan, and successively obtained "Jilin non-public economic tax payer", "small giant enterprise", "top 100 non-public enterprises", "top 100 private enterprises in Jilin Province", "advanced private enterprises in Northeast China", "top 100 national traditional Chinese medicine enterprises", "national level High tech enterprise, national youth civilization enterprise, national key leading enterprise of agricultural industrialization and other honorary titles. "Zixin" trademark is awarded as China's well-known trademark and Jilin province's famous trademark. Mr. Guo Chunsheng, chairman of the company, was elected as the deputy of Jilin Provincial People's Congress and the provincial soft environment governance inspector. The main products of Zixin pharmaceutical are Huoxue Tongmai tablet, Shexiang Jiegu capsule, xingnaozaizao capsule, Fufang Yiganling tablet, Bushen Anshen oral liquid, Simiao pill, etc. The dosage forms include tablet, capsule, granule, pill, oral solution, mixture and lozenge. The production workshops of all dosage forms have obtained GMP certification. At the same time, the company has a high-level scientific research team engaged in the development of new products, protection of pharmaceutical intellectual property rights, in-depth research of old products and other work, laying a solid foundation for the company's product promotion and sales. Among the company's products, 21 kinds of drugs are listed in OTC varieties, 18 in Category A, 3 in category B, and Bushen Anshen oral liquid is the exclusive OTC variety; 29 kinds of drugs are listed in the catalogue of drugs for national basic medical insurance and industrial injury insurance, 8 in Category A, 21 in category B, and Simiao pill is the exclusive variety; xingnaozaibao capsule, Huoxuetongmai tablet, Fufang Yiganling tablet Suoyang Bushen capsule and Simiao pill are the second-class protected varieties of traditional Chinese medicine. Huoxuetongmai tablet and Xiaoyanlidan tablet are national high-quality and high-priced products. Simiao pill, compound Yiganling tablet, xingnaozaibao capsule, Bushen Anshen oral liquid and Huganning tablet have been named as famous brand products of Jilin Province for many years. Zixin pharmaceutical has been carrying out production and operation activities in line with the quality consciousness of "product quality concerns enterprise life, drug quality concerns patient life" and "two life concepts". Pay close attention to the planting quality of traditional Chinese medicine. The planting base of traditional Chinese medicine in the hinterland of Changbai Mountain covers an area of 7318 hectares. The planting of important raw materials for medicinal materials, such as Panax ginseng, Amomum hyacinth, asarum, etc., from seed selection, seedling raising, planting, weeding and fertilization, to harvesting, processing and storage, is strictly in accordance with the gap standard. There are no heavy metals and pesticide residues in the raw materials, which ensure the high quality of raw materials at the source of production. Adopt the cooperation mode of new medicine planting. Adopt the four in one mode of "farmers government company research institute" to cultivate their own medicine base. This mode not only provides solid quality guarantee for the company's raw material supply and scientific research and development, but also drives the local rural industrialization development, and provides thousands of employment opportunities for the surrounding areas. Adhere to the business philosophy of "sincerity, quality and purity". From the selection of equipment, the recruitment of talents to the use of technology and the purchase of raw materials, we have achieved the most advanced, the best and the most refined. Each batch of products, from the feeding of traditional Chinese medicine to the observation of semi-finished products, finished products and reserved samples, are monitored according to the national legal standards, and one unqualified product is not allowed to leave the factory. Application of advanced production technology and equipment. High performance liquid chromatograph, ultraviolet visible spectrophotometer, tablet fineness tester, automatic inkjet printer and other advanced inspection equipment are used for quality inspection, and high-tech pharmaceutical processes such as ultra-fine crushing enzyme technology, carbon dioxide supercritical extraction technology, film coating technology, macroporous resin and additional separation technology are applied to production, and modern production lines abroad are introduced to dry the extract , granulation and coating are completed in one step, which improves the technological content of the product. Adhering to the "sales is the lifeblood of enterprise survival" sales philosophy. In terms of business strategy, the company has always put sales in an important position, clearly put forward the sales strategy of vigorously implementing the brand strategy, building a first-class sales team, improving the integrated sales system, realizing the five unification of product positioning, logistics scheduling, distribution assessment, price management, market division, optimizing resource allocation, and comprehensively creating a new situation in sales. Adhere to the principle of "people-oriented". The company has formulated effective systems and implementation procedures in R & D incentive mechanism, human resource allocation and technical management. Every employee has a stage of their own growth and performance in the company, everyone is equal before the opportunity, and the excellent talents and employees who have made outstanding contributions to the company are given reuse and heavy awards, which fully mobilize the enthusiasm of all employees. We are duty bound to take on social responsibility. Since its establishment, the company has been actively engaged in donation, road construction and other social public welfare undertakings to create nearly one thousand employment opportunities based on the principle of benefiting the public. Fulfill social responsibility wholeheartedly. After 13 years of growth and development, Zi Xin Pharmaceutical has already made the development and upgrading of products as the key to the rapid development of enterprises. It has built up a ladder like scientific research system with the generation generation, the reserve generation and the development of a generation, focusing on the treatment of the intestines, stomach system, anti aging and other medicines, accelerating the development of biological agents, and continuing to develop varieties of single drugs and groups, focusing on the state. Second and third class new drugs, and redevelopment of existing key varieties. At present, the company is investing a lot of funds in the development of cardiovascular, sedative and sedative drugs, gynecological drugs and other series of drugs. In combination with the changes of modern disease spectrum, the company has developed effective drugs for the treatment of cardiovascular, endocrine disorders, liver diseases and digestive system problems, forming a complete range of products with reasonable structure. Especially in the past two years, Zixin pharmaceutical industry has responded to the call of Jilin provincial government to develop ginseng industry and vigorously promoted the development of ginseng industry in Jilin Province. No matter in the planting base or in the development of scientific and technological products, a lot of human, material and financial resources have been invested. Huitong, a leading international research and development institution and Academy of Sciences, has made great achievements in the research of gene map of ginseng, application of ginseng enzyme technology, ginseng brewing technology, ginseng planting technology and high residual ginseng extract technology, and is in the leading position in the world. Actively guide and standardize the cultivation and cultivation market of high-quality ginseng, and strive to achieve industrial upgrading and effective transformation of scientific and technological achievements. In the face of the new situation that the Ministry of health officially approved Jilin Province to carry out the pilot work of ginseng medicine and food homology, Zixin pharmaceutical took the lead in introducing ginseng into the functional food and health product industries, and successfully developed more than 100 varieties, 41 of which have been approved for pilot production. Zixin pharmaceutical will make every effort to build the brand of Zixin ginseng, strive to realize the revitalization of ginseng industry in Jilin Province, and rebuild the international status of Jilin ginseng in China. Zixin pharmaceutical will continue to adhere to the enterprise tenet of "cultivating people by products and brewing medicine by virtue", the business philosophy of "sincerity, quality and purity", the business policy of "respecting knowledge, advocating science, excavating tradition and creating new knowledge", and take the health of the world as Zixin's responsibility. The future development goal of Zixin pharmaceutical industry will also inherit and carry forward the characteristics and advantages of traditional Chinese medicine, strive to tap the treasure house of traditional Chinese medicine, realize technological innovation and industrial upgrading, based on the domestic market, explore the international market, make the company move forward towards scientific, professional, intensive and international pharmaceutical enterprise groups, and contribute to the development of traditional Chinese medicine industry in China.

本文链接: https://brand.waitui.com/6b445f223.html

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

2小时前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

2小时前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

2小时前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

2小时前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

本页详细列出关于吉韩庄的品牌信息,含品牌所属公司介绍,吉韩庄所处行业的品牌地位及优势。
咨询